WeLeader Biomedical Co. Ltd. AI Stock Analysis
WeLeader Biomedical Co. Ltd. (7713) AI Stock Analysis
WeLeader Biomedical Co. Ltd.
(TPEx:7713)
The score is driven primarily by solid financial performance: accelerating revenue, dramatically expanded margins, rapid profit compounding, meaningful de-leveraging, and operating cash flow that exceeds reported earnings. Valuation reinforces the case, with a modest 12.9x P/E and a generous 5.82% dividend yield. The main drags are technical: the stock trades below its 20-, 50- and 100-day moving averages with a negative MACD, although deeply oversold momentum readings and a price still above the 200-day average suggest the longer-term trend has not broken. Key fundamental risks to watch are weak free cash flow conversion from elevated capex, a still-meaningful debt load relative to company size, and demonstrated sensitivity to demand swings.
WeLeader Biomedical Co. Ltd. (7713) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 3.21B
- Dividend Yield
- 5.81%
- Average Volume (3M)
- 6,715
- Price to Earnings (P/E)
- 12.2
- Beta (1Y)
- 0.26
- Revenue Growth
- 19.20%
- EPS Growth
- 34.00%
- Country
- TW
- Employees
- 209
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Distribution
WeLeader Biomedical Co. Ltd. Business Overview & Revenue Model
Company Description
WeLeader Biomedical Co. Ltd. is primarily involved in the development and distribution of medical diagnostic instruments and related supplies. The company offers specialized products such as integrated systems for serum biochemistry, alongside compre...
WeLeader Biomedical Co. Ltd. Financial Statement Overview
Summary
WeLeader Biomedical shows a strong and improving financial profile. Revenue re-accelerated to roughly 12% growth in 2025 (NT$1.11B), while margins expanded sharply over five years — gross margin to 33.4%, operating margin to 23.5%, and net margin to 18.8% — lifting net income more than fourfold to NT$208.6M. The balance sheet has de-levered meaningfully, with debt-to-equity falling from 1.63 to 0.69 as equity nearly quintupled, and ROE remains healthy at 16.6%. Operating cash flow of NT$302.8M exceeds net income, signalling good earnings quality. Offsetting these strengths are weak free cash flow conversion (NT$90M, about 30% of net income) due to heavy capex, a still-notable debt load of NT$864M for a company of this size, a declining ROE trend, and demand volatility evidenced by the 2023 revenue dip.
Income Statement
84Very PositiveBalance Sheet
73PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Jun 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.21B | 1.11B | 991.13M | 940.70M | 1.04B | 841.14M |
| Gross Profit | 424.28M | 370.97M | 316.32M | 298.08M | 291.75M | 218.92M |
| EBITDA | 441.49M | 384.25M | 329.59M | 303.04M | 306.57M | 252.06M |
| Net Income | 249.24M | 208.56M | 170.21M | 152.28M | 153.80M | 105.77M |
Balance Sheet | ||||||
| Total Assets | 2.52B | 2.45B | 2.00B | 1.73B | 1.60B | 883.09M |
| Cash, Cash Equivalents and Short-Term Investments | 122.73M | 334.71M | 212.17M | 104.95M | 111.45M | 118.71M |
| Total Debt | 978.95M | 863.64M | 796.77M | 626.00M | 701.25M | 285.11M |
| Total Liabilities | 1.32B | 1.19B | 1.09B | 881.78M | 954.19M | 525.67M |
| Stockholders Equity | 1.20B | 1.26B | 908.47M | 845.78M | 646.30M | 357.41M |
Cash Flow | ||||||
| Free Cash Flow | 184.01M | 90.03M | 104.50M | 116.13M | -381.38M | 214.13M |
| Operating Cash Flow | 329.16M | 302.77M | 278.76M | 231.86M | 280.27M | 238.03M |
| Investing Cash Flow | -186.14M | -275.40M | -196.65M | -113.96M | -665.27M | -2.71M |
| Financing Cash Flow | -180.52M | 35.37M | -1.83M | -123.94M | 374.22M | -225.96M |
WeLeader Biomedical Co. Ltd. Peers Comparison
Overall Rating
- TW:771374Outperform
TW:646142Neutral
TW:649241Neutral
TW:687537Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:7713 | 74Outperform | TWD 3.21B | 12.17 | ― | 5.81% | 19.20% | 34.00% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6461 | 42Neutral | TWD 2.94B | -5.62 | ― | ― | -57.87% | -21.67% |
| TW:6492 | 41Neutral | TWD 3.44B | -9.10 | ― | ― | 5.00% | -6.49% |
| TW:6875 | 37Underperform | TWD 3.24B | -9.23 | ― | ― | -69.26% | -24.53% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:7713 | WeLeader Biomedical Co. Ltd. | 70.60 | 0.26 | 0.36% | |
| TW:6461 | Intech Biopharm Ltd | 26.20 | 1.30 | 5.24% | |
| TW:6492 | Senhwa Biosciences Inc | 30.10 | -13.07 | -30.28% | |
| TW:6838 | Formosa Pharmaceuticals, Inc. | 20.35 | -7.10 | -25.87% | |
| TW:6875 | Pharmosa Biopharm Inc. | 25.25 | -24.40 | -49.14% | |
| TW:6885 | BRIM Biotechnology, Inc. | 29.50 | -0.35 | -1.17% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026